Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company Deals

Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers

Fineline Cube Nov 14, 2025

Adagene Inc. (NASDAQ: ADAG) and Third Arc Bio, Inc. announced today that they have signed...

Company Drug

Gan & Lee’s Ondibta Receives Positive CHMP Opinion – EU Biosimilar Pathway Opened

Fineline Cube Nov 14, 2025

Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced that the European Medicines Agency (EMA) has...

Company Drug

Corxel Secures FDA IND Clearance for CX11 Phase 2 Trial in Type 2 Diabetes

Fineline Cube Nov 14, 2025

Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared...

Company Deals

Pfizer Reduces BioNTech Holding by 54.7% While Collaboration Remains Intact

Fineline Cube Nov 14, 2025

Pfizer Inc. (NYSE: PFE) disclosed on November 13, 2025 that it has sold a portion of its...

Company Drug

Jiangsu Hengrui’s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase III Prostate‑Cancer Trial

Fineline Cube Nov 14, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced today that its second‑generation androgen‑receptor inhibitor...

Company Drug

Legend Biotech Reports $524 M CARVYKTI Sales, FDA Updates & Q3 Loss

Fineline Cube Nov 13, 2025

Legend Biotech (NASDAQ: LEGN) published the unaudited financial results for fiscal Quarter 3 2025 (2025Q3) on 12 Nov 2025. The flagship...

Company Drug

Tonghua Dongbao Secures Dominican Republic Market Launch for Insulin Aspart

Fineline Cube Nov 13, 2025

Tonghua Dongbao Pharmaceuticals Co., Ltd. (SHA: 600867) announced that its Insulin Aspart Injection 3 ml : 300 IU pre‑filled...

Company Drug

BCHT Receives NMPA Approval for First Adult DTaP Vaccine Covering Pertussis, Diphtheria, and Tetanus

Fineline Cube Nov 13, 2025

Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276) announced that its Adsorbed Acellular Pertussis (Two‑Component) Diphtheria...

Company Deals Drug

EirGenix Secures $152 M Licensing Deal for EG1206A Breast‑Cancer Biosimilar from Sandoz

Fineline Cube Nov 13, 2025

EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX:...

Company Drug

Humanwell Initiates Phase 2 Trial of HW231019 Tablets for Post‑Abdominal Surgery Analgesia

Fineline Cube Nov 13, 2025

Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase 2 clinical...

Company Deals

Bio‑Sincerity Secures XPO1 Inhibitor Deal for BIOS‑0629, Aims at Solid‑Tumor Expansion

Fineline Cube Nov 13, 2025

Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology...

Company

Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth

Fineline Cube Nov 13, 2025

Bayer AG (ETR: BAYN) announced on November 12 2025 that its third‑quarter 2025 (2025Q3) performance matched prior‑year...

Policy / Regulatory

FDA Announces New ‘Plausible‑Mechanism’ Pathway to Rapid Approvals for Rare Disease Treatments

Fineline Cube Nov 13, 2025

The U.S. Food and Drug Administration (FDA) announced on Wednesday a landmark regulatory shift that could...

Company Deals

Complete Genomics and SOPHiA Genetics Join Forces to Deliver End‑to‑End Oncology Validation on MGI’s T1+ Sequencing Platform

Fineline Cube Nov 13, 2025

Complete Genomics, the U.S. subsidiary of MGI Technologies (SHA: 688114), announced today a strategic collaboration...

Company Deals

Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders

Fineline Cube Nov 13, 2025

Degron Therapeutics, a China‑based pioneer in protein‑degradation therapies, today announced the signing of a Letter...

Company Deals

Adicon Holdings, Crown Bioscience, and Global Lab Services Forge New Integrated Platform for Oncology Translational Research

Fineline Cube Nov 13, 2025

Adicon Holdings Ltd. (HKG: 9860), a leading independent clinic laboratory (ICL) service provider in China,...

Company Deals

AbbVie to End 11‑Year R&D Alliance with Alphabet‑Owned Calico Labs

Fineline Cube Nov 13, 2025

AbbVie Inc. (NYSE: ABBV) announced today that it will terminate its long‑standing collaboration agreement with...

Company Deals

ChengDa Biotechnology, IMCAS, and Beijing Key Laboratory for Synthetic Immunology Forge New Frontiers in Vaccine Manufacturing

Fineline Cube Nov 12, 2025

Liaoning ChengDa Biotechnology Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences (IMCAS)...

Company Deals

Sun‑Novo, Byterna, and CAR‑T/CircRNA Collaboration Propel In‑Vivo Gene‑Therapy Frontiers

Fineline Cube Nov 12, 2025

Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. today disclosed a strategic capital injection of RMB 15 million into...

Company Deals

Suzhou Forlong Biotech, Shanghai Henlius, and Engineered Cytokine Immunotherapy Collaboration Announced

Fineline Cube Nov 12, 2025

Suzhou Forlong Biotechnology Co., Ltd. today revealed a strategic partnership with Shanghai Henlius Biotech, Inc....

Posts pagination

1 … 73 74 75 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.